company background image
EMD

EmyriaASX:EMD Stock Report

Market Cap

AU$55.9m

7D

4.7%

1Y

192.2%

Updated

18 Oct, 2021

Data

Company Financials
EMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EMD Overview

Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics.

Emyria Competitors

Skylight Health Group

TSXV:SLHG

CA$140.0m

Price History & Performance

Summary of all time highs, changes and price drops for Emyria
Historical stock prices
Current Share PriceAU$0.23
52 Week HighAU$0.069
52 Week LowAU$0.27
Beta0
1 Month Change-4.26%
3 Month Change18.42%
1 Year Change192.21%
3 Year Changen/a
5 Year Changen/a
Change since IPO55.17%

Recent News & Updates

Jun 11
We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Emyria ( ASX:EMD...

Shareholder Returns

EMDAU HealthcareAU Market
7D4.7%-1.3%0.9%
1Y192.2%11.5%20.2%

Return vs Industry: EMD exceeded the Australian Healthcare industry which returned 11.5% over the past year.

Return vs Market: EMD exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is EMD's price volatile compared to industry and market?
EMD volatility
EMD Beta0
Industry Beta0.61
Market Beta1

Stable Share Price: EMD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: EMD's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018n/aMichael Winlohttps://www.emyria.com

Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics. Its product pipeline include EMD-003, a cannabinoid medicine for treating patients with mental health; and EMD-004, a cannabinoid medicine targeting irritable bowel syndrome. The company also provides a data platform that manages, monitors, and improves the safety and efficacy of novel treatments for patients with unmet medical needs.

Emyria Fundamentals Summary

How do Emyria's earnings and revenue compare to its market cap?
EMD fundamental statistics
Market CapAU$55.90m
Earnings (TTM)-AU$4.91m
Revenue (TTM)AU$1.98m

29.0x

P/S Ratio

-11.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EMD income statement (TTM)
RevenueAU$1.98m
Cost of RevenueAU$2.26m
Gross Profit-AU$288.36k
ExpensesAU$4.62m
Earnings-AU$4.91m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.019
Gross Margin-14.59%
Net Profit Margin-248.30%
Debt/Equity Ratio0%

How did EMD perform over the long term?

See historical performance and comparison

Valuation

Is Emyria undervalued compared to its fair value and its price relative to the market?

7.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EMD is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.

PE vs Market: EMD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EMD is overvalued based on its PB Ratio (8x) compared to the AU Healthcare industry average (2.1x).


Future Growth

How is Emyria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

2.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Emyria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Emyria performed over the past 5 years?

6.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: EMD is currently unprofitable.

Growing Profit Margin: EMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if EMD's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare EMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).


Return on Equity

High ROE: EMD has a negative Return on Equity (-68.35%), as it is currently unprofitable.


Financial Health

How is Emyria's financial position?


Financial Position Analysis

Short Term Liabilities: EMD's short term assets (A$6.9M) exceed its short term liabilities (A$1.0M).

Long Term Liabilities: EMD's short term assets (A$6.9M) exceed its long term liabilities (A$849.1K).


Debt to Equity History and Analysis

Debt Level: EMD is debt free.

Reducing Debt: EMD had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 36.8% each year.


Dividend

What is Emyria current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EMD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Michael Winlo

1.92yrs

Tenure

AU$470,544

Compensation

Dr. Michael Winlo serves as Managing Director of Emyria Limited (formerly known as Emerald Clinics Limited) since November 26, 2019 and served as its Chief Executive Officer until November 26, 2019. Dr. Wi...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD349.25K) is about average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EMD's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: EMD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.


Top Shareholders

Company Information

Emyria Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Emyria Limited
  • Ticker: EMD
  • Exchange: ASX
  • Founded: 2018
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: AU$55.900m
  • Shares outstanding: 254.09m
  • Website: https://www.emyria.com

Location

  • Emyria Limited
  • D2, 661 Newcastle Street
  • Leederville
  • Western Australia
  • 6007
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:03
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.